Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hugosson

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
The Prostate|February 19, 2000
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatmentG Ahlgren, K Pedersen, S Lundberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2013
Prostate cancer: ESMO Consensus Conference Guidelines 2012A Horwich, J Hugosson, T de Reijke, et al.
European Urology|January 1, 1994
Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancerG Aus, S Brändstedt, M Häggman, et al.
The Journal of Urology|February 25, 1998
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigenP Lodding, G Aus, S Bergdahl, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2001
Bone marrow micrometastases in patients with stage I-II localised prostate cancerV Vagunda, K Landys, J P Kankkunen, et al.
BJU International|June 10, 2000
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in SwedenJ Hugosson, G Aus, C Becker, et al.
The Journal of Urology|May 23, 1998
Hormonal treatment before radical prostatectomy: a 3-year followupG Aus, P A Abrahamsson, G Ahlgren, et al.
BJU International|September 17, 2002
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trialG Aus, P-A Abrahamsson, G Ahlgren, et al.
European Urology|January 1, 1996
The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatmentJ Hugosson, P A Abrahamsson, G Ahlgren, et al.
BJU International|February 27, 2004
Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in SwedenJ Hugosson, G Aus, S Bergdahl, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
The Prostate|February 19, 2000
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatmentG Ahlgren, K Pedersen, S Lundberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 11, 2013
Prostate cancer: ESMO Consensus Conference Guidelines 2012A Horwich, J Hugosson, T de Reijke, et al.
European Urology|January 1, 1994
Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancerG Aus, S Brändstedt, M Häggman, et al.
The Journal of Urology|February 25, 1998
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigenP Lodding, G Aus, S Bergdahl, et al.
European Journal of Cancer (Oxford, England : 1990)|September 29, 2001
Bone marrow micrometastases in patients with stage I-II localised prostate cancerV Vagunda, K Landys, J P Kankkunen, et al.
BJU International|June 10, 2000
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in SwedenJ Hugosson, G Aus, C Becker, et al.
The Journal of Urology|May 23, 1998
Hormonal treatment before radical prostatectomy: a 3-year followupG Aus, P A Abrahamsson, G Ahlgren, et al.
BJU International|September 17, 2002
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trialG Aus, P-A Abrahamsson, G Ahlgren, et al.
European Urology|January 1, 1996
The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatmentJ Hugosson, P A Abrahamsson, G Ahlgren, et al.
BJU International|February 27, 2004
Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in SwedenJ Hugosson, G Aus, S Bergdahl, et al.
Pageof 7